|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
WednesdayPegylated Interferon Beta-1a for Multiple Sclerosis: VIDEOThe MD Magazine Peer Exchange "Modifying the Course of Multiple Sclerosis in New Ways: The Latest Advances in Treatment" features a distinguished panel of physician experts discussing key topics in multiple sclerosis (MS) research and management, including the latest insights into MS pathophysiology, new medication options and their application in clinical practice, and more. Read more » Labels: Aubagio, Lemtrada, Plegridy, Tecfidera, Video FREE MS RESEARCH UPDATE: a comprehensive overview of research findings on all of the FDA-approved disease-modifying therapies, as well as many experimental treatments![]() This year's expanded MS Research Update incorporates new information about the approved disease-modifying therapies (DMTs), as well as numerous experimental drugs currently under investigation for the long-term treatment of multiple sclerosis (MS). Highlights and recent research results are provided for each drug. Please note that symptom-management drugs are not included in this report. DOWNLOAD YOUR FREE PDF OR ORDER A FREE COPY Labels: Aubagio, Avonex, Betaseron, Copaxone, Lemtrada, Rebif, Rituxan-Rituximab, Tecfidera, Tysabri SaturdayMerck KGaA shores up Rebif defenses to fend off new MS rivalsFREE MS RESEARCH UPDATE: a comprehensive overview of research findings on all of the FDA-approved disease-modifying therapies, as well as many experimental treatments![]() This year's expanded MS Research Update incorporates new information about the approved disease-modifying therapies (DMTs), as well as numerous experimental drugs currently under investigation for the long-term treatment of multiple sclerosis (MS). Highlights and recent research results are provided for each drug. Please note that symptom-management drugs are not included in this report. DOWNLOAD YOUR FREE PDF OR ORDER A FREE COPY Labels: Aubagio, Avonex, Betaseron, Copaxone, Extavia, Lemtrada, Rebif, Rituxan, Tecfidera, Tysabri FridaySanofi MS Drug Added With Genzyme Fails to Win FDA Approval
Sanofi (SAN) failed to win U.S. regulatory
approval for its multiple sclerosis drug Lemtrada, denting the
company’s ambitions of capturing a larger share of the $20
billion market for the disease.
The U.S. Food and Drug Administration said Sanofi’s Genzyme
unit didn’t submit evidence from “adequate and well-controlled
studies” showing that the benefits of Lemtrada outweigh its
side effects, the Paris-based company said in a statement today.
Sanofi disagrees with the conclusion and said it will appeal.Lemtrada, which was approved in the European Union in September, was a key part of Sanofi’s $20.1 billion acquisition of Genzyme in 2011. The FDA indicated one or more additional trials comparing Lemtrada with another drug are needed for approval, Sanofi said. That would delay the product’s entry to a market dominated by Teva Pharmaceutical Industries Ltd. (TEVA:US)’s Copaxone, Biogen Idec Inc. (BIIB:US)’s Tecfidera, Avonex and Tysabri, Novartis AGâs (NOVN) Gilenya and Merck KGaA’s Rebif. Read more » Labels: Avonex, Copaxone, Lemtrada, Rebif, Tecfidera, Tysabri BioTrends Research Group Rolls Out The TreatmentTrends: Multiple Sclerosis 2013 ReportBioTrends Research Group, a research and advisory firms for specialized biopharmaceutical issues, finds that physician-reported patient shares for Novartis's Gilenya and Biogen Idec's Tysabri are 8 percent and 10 percent among relapsing-remitting multiple sclerosis (RR-MS) patients treated with a disease-modifying therapy (DMT) across the EU5 (France, Germany, Italy, Spain and the United Kingdom); significantly higher than those reported by EU5 neurologists surveyed in 2012. According to a release, surveyed neurologists also report that recent changes in treatment management include a shift toward earlier and more-aggressive treatment and increased use of the anti- JCV antibody assay, changes that are consistent with the increased patient shares reported for Gilenya and Tysabri. Survey data indicate that these agents occupy distinct niches, with Gilenya a preferred second-line therapy in JCV-positive patients and Tysabri a preferred second-line therapy in JCV-negative patients. The TreatmentTrends: Multiple Sclerosis (EU) 2013 report finds that, despite fewer than 30 percent of surveyed neurologists reporting access to Genzyme's* Aubagio and Genzyme/Bayer HealthCare's Lemtrada--and given the limited time these agents had been available at the time the survey was fielded--these DMTs have nevertheless captured a 1 percent physician-reported weighted MS patient share. The data also reveal that surveyed neurologists anticipate substantial changes in DMT use in the coming months as access to Aubagio and Lemtrada expands and as new products, notably Biogen Idec's Tecfidera, become available. Neurologists indicate that Aubagio will most likely compete with first-line products (i.e., Biogen Idec's Avonex, Bayer HealthCare's Betaferon and Teva's Copaxone), while Tecfidera may replace these products as well as Merck Serono's Rebif and Gilenya. Lemtrada, conversely, will most likely compete with Tysabri or would not replace an existing DMT, suggesting anticipated use as a last-line therapy. "The European MS market is entering a dynamic period with two recent DMT launches and as many as six new DMTs launching in the next five years," said Decision Resources Group Senior Business Insights Analyst Georgiana L. Kuhlmann, S.M. "Our data find that gains for new brands will likely come at the expense of the interferon-beta therapies and Copaxone." BioTrends Research Group provides syndicated and custom primary market research to pharmaceutical manufacturers competing in clinically evolving, specialty pharmaceutical markets. Decision Resources Group is a cohesive portfolio of companies that offers information and insights on sectors of the healthcare industry. Read more » Labels: Aubagio, Avonex, Betaseron, Copaxone, Lemtrada, Rebif, Tecfidera, Tysabri Surveyed Neurologists Report Significantly Higher Relapsing-Remitting Multiple Sclerosis Patient Shares for Gilenya and Tysabri, Compared With One Year Ago![]() The TreatmentTrends: Multiple Sclerosis (EU) 2013 report finds that, despite fewer than 30 percent of surveyed neurologists reporting access to Genzyme's* Aubagio and Genzyme/Bayer HealthCare's Lemtrada—and given the limited time these agents had been available at the time the survey was fielded—these DMTs have nevertheless captured a 1 percent physician-reported weighted MS patient share. The data also reveal that surveyed neurologists anticipate substantial changes in DMT use in the coming months as access to Aubagio and Lemtrada expands and as new products, notably Biogen Idec's Tecfidera, become available. Neurologists indicate that Aubagio will most likely compete with first-line products (i.e., Biogen Idec's Avonex, Bayer HealthCare's Betaferon and Teva's Copaxone), while Tecfidera may replace these products as well as Merck Serono's Rebif and Gilenya. Lemtrada, conversely, will most likely compete with Tysabri or would not replace an existing DMT, suggesting anticipated use as a last-line therapy.
"The
European MS market is entering a dynamic period with two recent DMT
launches and as many as six new DMTs launching in the next five years,"
said Decision Resources Group Senior Business Insights Analyst Georgiana L. Kuhlmann, S.M. "Our data find that gains for new brands will likely come at the expense of the interferon-beta therapies and Copaxone."
Click here to read more Labels: Aubagio, Avonex, Copaxone, Lemtrada, Rebif, Tecfidera, Tysabri What Does a Mixed FDA Verdict Mean for Sanofi's MS Drug LEMTRADA? An
FDA advisory panel recently recommended the approval of Sanofi's
multiple sclerosis drug, Lemtrada. However, that approval came among
some mixed and contradictory opinions about the drug and the efficacy of
Sanofi's trials.On Nov. 13, the FDA panel voted 12-6 that Sanofi had provided enough evidence of Lemtrada's efficacy in patients with relapsed MS, but at the same time voted 11-6 that the company's trials had not been conducted thoroughly enough to properly assess the drug. After those seemingly contradictory opinions, the panel voted 14-0 that the drug should still be approved in December, despite its potential to cause cancer and other problems. Read more » Labels: Aubagio, Avonex, Copaxone, Lemtrada, Tecfidera, Tysabri BREAKING NEWS FDA GIVES MIXED BLESSING ON NEW MS DRUG: LEMTRADA (Campath, Alemtuzmab)After a scathing staff review, Sanofi walked away from an FDA panel with mixed messages on its long-delayed multiple sclerosis drug Lemtrada, as agency advisers said the injection wasn't too risky to approve but took issue with the drugmaker's trial design. The FDA's Peripheral and Central Nervous System Drugs Advisory Read more » Breaking News Update: Lemtrada (AKA: Alemtuzumab & Campath
FDA CASTS "FATAL" DOUBTS ON SANOFI'S LEMTRADA: THE ONCE-A-YEAR MS DRUG
CLICK HERE TO READ THE FDA'S OFFICIAL DOCUMENT ON LEMTRADA (Alemtuzumab) (Campath) Sanofi's multiple sclerosis drug Lemtrada may be too dangerous to warrant FDA approval, agency staff said! U.S. regulatory officials have raised concerns about "multiple serious and potentially fatal safety issues" in patients given Lemtrada. Read more » A Changing of the Guard in Treating Multiple Sclerosis![]() Recognizing the need for better treatment options, big pharma has a slate of new oral MS drugs hitting the market. Read more » Labels: Aubagio, Avonex, Copaxone, Lemtrada, Tecfidera, Tysabri Monday"European green light for new multiple sclerosis medicine Lemtrada (alemtuzumab) - once known as Campath"
LONDON
(Reuters) Jun 10 - One of the world's longest running drug development
sagas may draw to a close this month as French firm Sanofi hopes for a
European green light for its new multiple sclerosis medicine Lemtrada
(alemtuzumab) - once known as Campath.
After studying Lemtrada since the early 1990s, he believes the drug's infrequent infusions have a lot to offer patients.
Sanofi,
too, is optimistic about a medicine that would mark its second victory
in MS, following last year's U.S. approval of Aubagio, a pill. It
expects an EMA verdict by mid-year, implying a decision at the agency's
next expert meeting on June 24-27.
Labels: Aubagio, Lemtrada, Tecfidera, Tysabri |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||